{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:05:06Z","timestamp":1790521506103,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00204-024-03794-3","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T11:01:37Z","timestamp":1721300497000},"page":"3409-3424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC)"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-9885","authenticated-orcid":false,"given":"Vlasia","family":"Kastrinou-Lampou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Rodr\u00edguez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birk","family":"Poller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"G\u00e1borik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"M\u00e1rtonn\u00e9-T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"Temesszentandr\u00e1si-Ambrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko S.","family":"Schadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian","family":"Camenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"6","key":"3794_CR1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/hep.21424","volume":"44","author":"RJ Andrade","year":"2006","unstructured":"Andrade RJ, Lucena MI, Kaplowitz N, Garc\u00eda-Mu\u0146oz B, Borraz Y, Pachkoria K, Garc\u00eda-Cort\u00e9s M, Carmen Fern\u00e1ndez M, Pelaez G, Rodrigo L, Dur\u00e1n JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Mu\u0146oz-Yag\u00fce T, Salmer\u00f3n J, Hidalgo R (2006) Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44(6):1581\u20131588. https:\/\/doi.org\/10.1002\/hep.21424","journal-title":"Hepatology"},{"issue":"6","key":"3794_CR2","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.20961","volume":"42","author":"N Ballatori","year":"2005","unstructured":"Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N (2005) OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42(6):1270\u20131279. https:\/\/doi.org\/10.1002\/hep.20961","journal-title":"Hepatology"},{"key":"3794_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/B978-012639011-7\/50013-9","volume-title":"Blood-spinal cord and brain barriers in health and disease","author":"DJ Begley","year":"2004","unstructured":"Begley DJ (2004) Efflux mechanisms in the central nervous system: a powerful influence on drug distribution within the brain. In: Sharma HS, Westman J (eds) Blood-spinal cord and brain barriers in health and disease. Elsevier, Amsterdam, pp 83\u201397. https:\/\/doi.org\/10.1016\/B978-012639011-7\/50013-9"},{"issue":"2","key":"3794_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.11648\/j.ijpc.20190502.11","volume":"5","author":"G Camenisch","year":"2019","unstructured":"Camenisch G (2019) Extended Clearance Model and its use for prospective transporter and enzyme-based hepatic cell stress grading. Int J Pharm Chem 5(2):15\u201319. https:\/\/doi.org\/10.11648\/j.ijpc.20190502.11","journal-title":"Int J Pharm Chem"},{"issue":"2","key":"3794_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/toxsci\/kfx284","volume":"162","author":"R Chan","year":"2018","unstructured":"Chan R, Benet LZ (2018) Measures of BSEP inhibition in vitro are not useful predictors of DILI. Toxicol Sci 162(2):499\u2013508. https:\/\/doi.org\/10.1093\/toxsci\/kfx284","journal-title":"Toxicol Sci"},{"issue":"4","key":"3794_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 21(4):648\u2013653. https:\/\/doi.org\/10.1016\/j.drudis.2016.02.015","journal-title":"Drug Discov Today"},{"issue":"3","key":"3794_CR7","doi-asserted-by":"publisher","first-page":"G349","DOI":"10.1152\/ajpgi.00417.2002","volume":"284","author":"JY Chiang","year":"2003","unstructured":"Chiang JY (2003) Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol 284(3):G349\u2013G356. https:\/\/doi.org\/10.1152\/ajpgi.00417.2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"10","key":"3794_CR8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","volume":"50","author":"JY Chiang","year":"2009","unstructured":"Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50(10):1955\u20131966. https:\/\/doi.org\/10.1194\/jlr.R900010-JLR200","journal-title":"J Lipid Res"},{"issue":"1","key":"3794_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1124\/dmd.111.040758","volume":"40","author":"S Dawson","year":"2012","unstructured":"Dawson S, Stahl S, Paul N, Barber J, Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40(1):130\u2013138. https:\/\/doi.org\/10.1124\/dmd.111.040758","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3794_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/gut.2008.159541","volume":"58","author":"PH Dixon","year":"2009","unstructured":"Dixon PH, van Mil SW, Chambers J, Strautnieks S, Thompson RJ, Lammert F, Kubitz R, Keitel V, Glantz A, Mattsson L-A, Marschall H-U, Molokhia M, Moore GE, Linton KJ, Williamson C (2009) Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 58(4):537\u2013544. https:\/\/doi.org\/10.1136\/gut.2008.159541","journal-title":"Gut"},{"key":"3794_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/978-0-387-32833-1_379","volume-title":"The concise encyclopedia of statistics","author":"Y Dodge","year":"2008","unstructured":"Dodge Y (2008) Spearman rank correlation coefficient. In: Dodge Y (ed) The concise encyclopedia of statistics. Springer, New York, NY, pp 502\u2013505. https:\/\/doi.org\/10.1007\/978-0-387-32833-1_379"},{"issue":"8","key":"3794_CR12","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1124\/dmd.107.018663","volume":"36","author":"OA Fahmi","year":"2008","unstructured":"Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36(8):1698\u20131708. https:\/\/doi.org\/10.1124\/dmd.107.018663","journal-title":"Drug Metab Dispos"},{"issue":"16","key":"3794_CR13","doi-asserted-by":"publisher","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","volume":"273","author":"T Gerloff","year":"1998","unstructured":"Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273(16):10046\u201310050. https:\/\/doi.org\/10.1074\/jbc.273.16.10046","journal-title":"J Biol Chem"},{"issue":"10","key":"3794_CR14","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1021\/acs.chemrestox.5b00201","volume":"28","author":"K He","year":"2015","unstructured":"He K, Cai L, Shi Q, Liu H, Woolf TF (2015) Inhibition of MDR3 activity in human hepatocytes by drugs associated with liver injury. Chem Res Toxicol 28(10):1987\u20131990. https:\/\/doi.org\/10.1021\/acs.chemrestox.5b00201","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"3794_CR15","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1074\/jbc.275.4.2905","volume":"275","author":"T Hirohashi","year":"2000","unstructured":"Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y (2000) ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 275(4):2905\u20132910. https:\/\/doi.org\/10.1074\/jbc.275.4.2905","journal-title":"J Biol Chem"},{"issue":"5","key":"3794_CR16","first-page":"651","volume":"22","author":"TL Jansen","year":"2004","unstructured":"Jansen TL, Reinders MK, van Roon EN, Brouwers JR (2004) Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d? Clin Exp Rheumatol 22(5):651","journal-title":"Clin Exp Rheumatol"},{"key":"3794_CR17","doi-asserted-by":"publisher","first-page":"105533","DOI":"10.1016\/j.tiv.2022.105533","volume":"87","author":"V Kastrinou Lampou","year":"2022","unstructured":"Kastrinou Lampou V, Poller B, Huth F, Fischer A, Kullak-Ublick GA, Arand M, Schadt HS, Camenisch G (2022) Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes. Toxicol in Vitro 87:105533. https:\/\/doi.org\/10.1016\/j.tiv.2022.105533","journal-title":"Toxicol in Vitro"},{"issue":"4","key":"3794_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/dmd.113.054304","volume":"42","author":"K Kock","year":"2014","unstructured":"Kock K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL (2014) Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 42(4):665\u2013674. https:\/\/doi.org\/10.1124\/dmd.113.054304","journal-title":"Drug Metab Dispos"},{"key":"3794_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100087","volume":"62","author":"T Kroll","year":"2021","unstructured":"Kroll T, Smits SHJ, Schmitt L (2021) Monomeric bile acids modulate the ATPase activity of detergent-solubilized ABCB4\/MDR3. J Lipid Res 62:100087. https:\/\/doi.org\/10.1016\/j.jlr.2021.100087","journal-title":"J Lipid Res"},{"issue":"2","key":"3794_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/01.mcg.0000196406.15110.60","volume":"40","author":"R Kubitz","year":"2006","unstructured":"Kubitz R, Keitel V, Scheuring S, Kohrer K, Haussinger D (2006) Benign recurrent intrahepatic cholestasis associated with mutations of the bile salt export pump. J Clin Gastroenterol 40(2):171\u2013175. https:\/\/doi.org\/10.1097\/01.mcg.0000196406.15110.60","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"3794_CR21","doi-asserted-by":"publisher","first-page":"G271","DOI":"10.1152\/ajpgi.00075.2007","volume":"293","author":"C Mahagita","year":"2007","unstructured":"Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N (2007) Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 293(1):G271\u2013G278. https:\/\/doi.org\/10.1152\/ajpgi.00075.2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"3794_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00228-004-0888-z","volume":"61","author":"Y Meier","year":"2005","unstructured":"Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K (2005) Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 61(2):135\u2013143. https:\/\/doi.org\/10.1007\/s00228-004-0888-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3794_CR23","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1124\/dmd.109.027797","volume":"37","author":"S Nakayama","year":"2009","unstructured":"Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37(9):1970\u20131977. https:\/\/doi.org\/10.1124\/dmd.109.027797","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"3794_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","volume":"453","author":"AT Nies","year":"2007","unstructured":"Nies AT, Keppler D (2007) The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453(5):643\u2013659. https:\/\/doi.org\/10.1007\/s00424-006-0109-y","journal-title":"Pflugers Arch"},{"issue":"1","key":"3794_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","volume":"32","author":"H Olson","year":"2000","unstructured":"Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32(1):56\u201367. https:\/\/doi.org\/10.1006\/rtph.2000.1399","journal-title":"Regul Toxicol Pharmacol"},{"key":"3794_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/9781119171003.ch15","volume-title":"Transporters and drug-metabolizing enzymes in drug toxicity","author":"B Poller","year":"2021","unstructured":"Poller B, Huth F, Kastrinou-Lampou V, Kullak-Ublick GA, Arand M, Camenisch G (2021) The extended clearance model. In: Li AP (ed) Transporters and drug-metabolizing enzymes in drug toxicity. Wiley, Hoboken, NJ, pp 455\u2013479. https:\/\/doi.org\/10.1002\/9781119171003.ch15"},{"issue":"3","key":"3794_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/03602532.2018.1483401","volume":"50","author":"SP Rendic","year":"2018","unstructured":"Rendic SP, Peter Guengerich F (2018) Human cytochrome P450 enzymes 5\u201351 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition \u2013 toxic effects and benefits. Drug Metab Rev 50(3):256\u2013342. https:\/\/doi.org\/10.1080\/03602532.2018.1483401","journal-title":"Drug Metab Rev"},{"issue":"5","key":"3794_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1124\/dmd.116.074179","volume":"45","author":"J Riede","year":"2017","unstructured":"Riede J, Poller B, Huwyler J, Camenisch G (2017) Assessing the risk of drug-induced cholestasis using unbound intrahepatic concentrations. Drug Metab Dispos 45(5):523\u2013531. https:\/\/doi.org\/10.1124\/dmd.116.074179","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3794_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1517\/17425255.3.1.51","volume":"3","author":"RJ Riley","year":"2007","unstructured":"Riley RJ, Grime K, Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3(1):51\u201366. https:\/\/doi.org\/10.1517\/17425255.3.1.51","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"3794_CR30","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"M Roth","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165(5):1260\u20131287. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01724.x","journal-title":"Br J Pharmacol"},{"issue":"Suppl","key":"3794_CR31","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","volume":"50","author":"DW Russell","year":"2009","unstructured":"Russell DW (2009) Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 50(Suppl):S120\u2013S125. https:\/\/doi.org\/10.1194\/jlr.R800026-JLR200","journal-title":"J Lipid Res"},{"issue":"42","key":"3794_CR32","doi-asserted-by":"publisher","first-page":"39411","DOI":"10.1074\/jbc.M106340200","volume":"276","author":"EG Schuetz","year":"2001","unstructured":"Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD (2001) Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276(42):39411\u201339418. https:\/\/doi.org\/10.1074\/jbc.M106340200","journal-title":"J Biol Chem"},{"issue":"3","key":"3794_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","volume":"75","author":"JJ Smit","year":"1993","unstructured":"Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CAAM, Ottenhoff R, van der Lugt NMT, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM, Borst P (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75(3):451\u2013462. https:\/\/doi.org\/10.1016\/0092-8674(93)90380-9","journal-title":"Cell"},{"issue":"2","key":"3794_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3748\/wjg.v21.i2.699","volume":"21","author":"HZ Sun","year":"2015","unstructured":"Sun HZ, Shi H, Zhang SC, Shen XZ (2015) Novel mutation in a Chinese patient with progressive familial intrahepatic cholestasis type 3. World J Gastroenterol 21(2):699\u2013703. https:\/\/doi.org\/10.3748\/wjg.v21.i2.699","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3794_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.drudis.2019.09.022","volume":"25","author":"S Thakkar","year":"2020","unstructured":"Thakkar S, Li T, Liu Z, Wu L, Roberts R, Tong W (2020) Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity. Drug Discov Today 25(1):201\u2013208. https:\/\/doi.org\/10.1016\/j.drudis.2019.09.022","journal-title":"Drug Discov Today"},{"issue":"8","key":"3794_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","volume":"7","author":"C Thomas","year":"2008","unstructured":"Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7(8):678\u2013693. https:\/\/doi.org\/10.1038\/nrd2619","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"3794_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1152\/physrev.00027.2002","volume":"83","author":"M Trauner","year":"2003","unstructured":"Trauner M, Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83(2):633\u2013671. https:\/\/doi.org\/10.1152\/physrev.00027.2002","journal-title":"Physiol Rev"},{"issue":"5","key":"3794_CR38","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00204-018-2201-4","volume":"92","author":"M Vinken","year":"2018","unstructured":"Vinken M (2018) In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist. Arch Toxicol 92(5):1909\u20131912. https:\/\/doi.org\/10.1007\/s00204-018-2201-4","journal-title":"Arch Toxicol"},{"key":"3794_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.761255","volume":"12","author":"Y Zu","year":"2021","unstructured":"Zu Y, Yang J, Zhang C, Liu D (2021) The pathological mechanisms of estrogen-induced cholestasis: current perspectives. Front Pharmacol 12:761255. https:\/\/doi.org\/10.3389\/fphar.2021.761255","journal-title":"Front Pharmacol"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-024-03794-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T18:04:12Z","timestamp":1731607452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-024-03794-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3794"],"URL":"https:\/\/doi.org\/10.1007\/s00204-024-03794-3","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Charles River Laboratories Hungary, SOLVO Biotechnology, the employer of some of the authors (Z. G., B. M-T., C. T-A.) develops and commercializes reagents and assays to study membrane transporters and metabolizing enzymes. M. A. is a member of the editorial board of Archives of Toxicology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}